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Abstract: B cell superantigens, also called immunoglobulin superantigens, bind to the variable regions
of either the heavy or light chain of immunoglobulins mirroring the lymphocyte-activating properties
of classical T cell superantigens. Protein A of Staphylococcus aureus, protein L of Peptostreptococcus
magnus, and gp120 of HIV are typical immunoglobulin superantigens. Mast cells are immune cells
expressing the high-affinity receptor for IgE (FcεRI) and are strategically located in the human
heart, where they play a role in several cardiometabolic diseases. Here, we investigated whether
immunoglobulin superantigens induced the activation of human heart mast cells (HHMCs). Protein
A induced the de novo synthesis of cysteinyl leukotriene C4 (LTC4) from HHMCs through the
interaction with IgE VH3+ bound to FcεRI. Protein L stimulated the production of prostaglandin D2
(PGD2) from HHMCs through the interaction with κ light chains of IgE. HIV glycoprotein gp120
induced the release of preformed (histamine) and de novo synthesized mediators, such as cysteinyl
leukotriene C4 (LTC4), angiogenic (VEGF-A), and lymphangiogenic (VEGF-C) factors by interacting
with the VH3 region of IgE. Collectively, our data indicate that bacterial and viral immunoglobulin
superantigens can interact with different regions of IgE bound to FcεRI to induce the release of
proinflammatory, angiogenic, and lymphangiogenic factors from human cardiac mast cells.
Keywords: angiogenesis; heart; histamine; IgE; leukotriene C4; lymphangiogenesis; mast cells;
myocardial infarction; prostaglandin D2; superantigens
1. Introduction
The term “superantigen” (SAg) refers to several proteins synthesized by a variety of bacteria and
viruses that not only mimic, but also exceed the activity of conventional antigens in activating T and B
cells [1–5]. Typical antigens are processed by antigen-presenting cells (APCs) into small peptides that
bind a distal groove in the molecules of the major histocompatibility complex (MHC) [6]. The peptide:
MHC (p:MHC) complex on the APC surface acts as a ligand of both T cell receptor (TCR) α and TCR β
variable domains on a few specific T cell clones. By contrast, SAgs bind directly to the lateral surfaces
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of the MHC class II molecules and to the Vβ domain of the TCR and thus bypass the processing and
presentation of conventional antigens by APCs [7–10]. As a result, conventional antigens stimulate
less than 1 in 10,000–100,000 T cells, while SAgs can stimulate up to 20% of all T cells [1,3]. A wide
range of diseases from autoimmune and allergic disorders, neoplasia, and immunodeficiencies can be
associated with SAgs [11–15].
In addition to classical T cell Sags, there are also B cell SAgs endowed with immunoglobulin
(Ig)-binding capacity. In contrast to conventional antigens, which bind to both the heavy and light chain
variable (V)-domains of Igs, B cell SAgs bind to the conserved sides of either the heavy (H)- or light
(L)-chain [16–18], resulting in a massive proliferation of B cells. Staphylococcus aureus (S. aureus) is a
source of several T cell SAgs (S. aureus enterotoxins: SE) [19]. Two staphylococcal B cell SAgs, S. aureus
protein A and SEA, bind specifically to VH3 domain of human Igs, whereas SED, which is also a T cell
SAg, binds to VH4 [11]. VH3 is the largest of human Ig germline VH families; thereby, protein A can
stimulate almost half of the B cells in the circulation [17]. Protein A is the archetypal B cell SAg and
contains five homologous repeated domains, each of which can bind to all or most of the VH3+ Igs.
S. aureus is a common pathogen causing toxic shock syndrome and endocarditis [20,21]. Most of clinical
isolates of S.aureus synthesize protein A, which can be released from the cell wall [22]. Protein A has two
binding sites for human Igs: the classical site binds Fcγ, a constant region of IgG [23] and an alternative
site that binds the Fab portion of 15% to 50% of human polyclonal IgG, IgM, IgA, and IgE [24].
Similarly, glycoprotein 120 (gp120) of HIV-1 is a viral B cell SAg, because it interacts with Ig
VH3+ [25,26]. The entry of HIV into host cells is mediated the interaction of viral glycoprotein [27]
gp120 with CD4 [28] and chemokine receptors on the cell surface [29,30]. HIV gp120 is a member of
the Ig SAg family [31–33]. Emergence of cardiovascular disease has become a leading concern for
patients with HIV infection [34,35].
Protein L is a cell wall protein synthesized by Peptostreptococcus magnus (P. magnus) [36]. Protein L
is a multi-domain protein that binds to some κ light chain variable domain without interfering with
the antigen-binding site [37,38]. Protein L binds to the V domain of the κ light chains of Igs [39–41].
In particular, protein L binds with high affinity (~1010 M−1) only human Vk I, Vk III and Vk IV subtypes,
but does not interact with Vk II subtype [42].
Mast cells are tissue resident immune cells present in most connective tissues including murine [43–45],
canine [46,47], and human heart [48–51]. Mast cells are canonically considered key effectors of allergic
responses [52–56] and are critical sentinels in immunity [57,58]. Mast cells and their mediators
participate in a variety of pathophysiological processes including response to infections [58–60],
angiogenesis [61–65], lymphangiogenesis [61,66], autoimmune disorders [67–69], cancer [70–73], and
cardiometabolic diseases [49,74–78].
Human mast cells express the high-affinity receptor (FcεRI) for immunoglobulin E (IgE) and
cross-linking of the IgE-FcεRI network induces the release of preformed (e.g., histamine, tryptase,
chymase) and de novo synthesized lipid mediators (e.g., prostaglandin D2 (PGD2), cysteinyl leukotriene
C4 (LTC4)). We have previously shown that several immune cells, such as human lung mast cells [61],
basophils [79], macrophages [80,81], and neutrophils [82], produce angiogenic (e.g., vascular endothelial
growth factor A:VEGF-A) and/or lymphangiogenic factors (e.g., vascular endothelial growth factor C:
VEGF-C) [52,61,81]. However, there is a marked heterogeneity of human mast cells with respect to the
mediators released from cells isolated from different anatomic sites [83–85].
This study has been undertaken to evaluate whether bacterial (protein A and protein L) and viral
(gp120) superantigens induce the release of proinflammatory, angiogenic, and lymphangiogenic factors
from human cardiac mast cells.
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2. Results
2.1. Effect of Human IgG Anti-IgE on Mediator Release from HHMCs
We have previously reported that IgG anti-IgE purified from the serum of a small percentage
of atopic dermatitis patients can induce histamine and LTC4 release from human basophils [86].
The activating property of human IgG anti-IgE (H-aIgE) is mediated by the interaction with
membrane-bound IgE on human basophils. Therefore, we used this human autoantibody to activate
human heart mast cells (HHMCs) in vitro. Figure 1 shows that H-aIgE (10−2 to 3 µg/mL) induced
a concentration-dependent histamine release from five different preparations of HHMCs. Four
preparations of IgG (10−2 to 3 µg/mL) purified from the serum of normal donors did not cause
histamine release (data not shown). These results suggest that mast cells isolated from human heart
express IgE bound to FcεRI.
Figure 1. Effect of increasing concentrations of human IgG anti-IgE purified from the serum of a patient
with atopic dermatitis [86] on histamine release from five different preparations of human heart mast
cells (HHMCs). HHMCs were incubated (45 min at 37 ◦C) with the indicated concentrations of human
IgG anti-IgE. Each point shows the mean of duplicate determinations. Each symbol represents the
results from an individual donor.
Vascular endothelial growth factors (VEGFs) are involved in new vessel formation and play
a central role in cardiac pathophysiology [87]. Therefore, we evaluated the release of angiogenic
(VEGF-A) and lymphangiogenic factors (VEGF-C) induced by H-aIgE from HHMCs. Figure 2 shows
that H-aIgE induced a concentration-dependent release of both VEGF-A and VEGF-C from four
different preparations of HHMCs.
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Figure 2. Effect of increasing concentrations of human IgG anti-IgE on the release of vascular endothelial
growth factor-A (VEGF-A) and vascular endothelial growth factor-C (VEGF-C) from HHMCs from
four donors. HHMCs were incubated (6 h at 37 ◦C) in the presence of the indicated concentrations of
human IgG anti-IgE. Each bar is the mean ± SEM. * p < 0.05; ** p < 0.01.
2.2. Effect of Bacterial Superantigens on Mediator Release from HHMCs
Figure 3A shows that protein A induced a concentration-dependent release of LTC4 from four
different preparations of HHMC. To evaluate the mechanism by which protein A activates HHMCs, it
was preincubated with human monoclonal IgM possessing different VH domains. Figure 3B shows
that human monoclonal IgM VH3+ dose-dependently inhibited the LTC4-releasing activity of protein
A. By contrast, human monoclonal IgM VH6+ had no inhibitory effect. These findings are compatible
with the hypothesis that protein A activates HHMCs through the binding to IgE VH3+ bound on FcεRI.
Figure 3. (A) Effect of increasing concentrations of protein A on the de novo synthesis of cysteinyl
leukotriene C4 (LTC4) from four different preparations of HHMCs. HHMCs were incubated (45 min
at 37 ◦C) with the indicated concentrations of protein A. Each point shows the mean of duplicate
determinations. Each symbol represents the results from an individual donor. (B) Effect of preincubation
of protein A with human monoclonal IgM on the activation of HHMCs. Protein A (300 nM) was
preincubated (15 min at 37 ◦C) with increasing concentrations (1 to 10 µg/mL) of human monoclonal
IgM VH3+ or IgM VH6+. HHMCs were then added and incubation continued for another 45 min at
37 ◦C. Each point shows the mean of duplicate determinations of a representative experiment. Similar
results were obtained in two other experiments.
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We have previously found that P. magnus and protein L activate human basophils and mast
cells [39,41]. Figure 4A shows that increasing concentrations of protein L induced de novo synthesis of
PGD2 from HHMCs. The activating property of protein L (100 nM) was inhibited by preincubation
with increasing concentrations (0.1 to 3 µg/mL) of human monoclonal IgE k, but not by two human
monoclonal IgE λ (Figure 4B). These results are compatible with the hypothesis that protein L activates
HHMCs through the interaction with the k light chain of IgE on cardiac mast cells.
Figure 4. (A) Effect of increasing concentrations of protein L on the de novo synthesis of prostaglandin
D2 (PGD2) from four different preparations of HHMCs. HHMCs were incubated (45 min at 37 ◦C)
with the indicated concentrations of protein L. Each point shows the mean of duplicate determinations.
Each symbol represents the results from an individual donor. (B) Effect of preincubation of protein
L with human monoclonal IgE on the activation of HHMCs. Protein L (100 nM) was preincubated
(15 min at 37 ◦C) with increasing concentrations (0.1 to 3 µg/mL) of two human monoclonal IgE λ light
chain and one human monoclonal IgE κ light chain and incubation continued for another 45 min at
37 ◦C. Each point shows the mean of duplicate determinations of PGD2 of a representative experiment.
Similar results were obtained in two other experiments.
2.3. Effect of Viral Superantigens on Mediator Release from HHMCs
Figure 5 shows the results of four independent experiments in which we incubated HHMCs
with recombinant gp120. These experiments demonstrated that increasing concentrations of gp120
stimulated the release of histamine (Figure 5A) and the de novo synthesis of LTC4 from HHMCs
(Figure 5B). Preincubation of gp120 (30 nM) with increasing concentrations (0.1 to 3 µg/mL) of human
monoclonal IgE VH3+ inhibited the releasing activity of gp120 (data not shown). These results indicate
that gp120 activates HHMCs by interacting with IgE VH3+ bound to FcεRI.
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Figure 5. Effect of increasing concentrations of human immunodeficiency virus (HIV) gp120 on
mediator release from four different preparations of HHMCs. HHMCs were incubated (45 min at 37 ◦C)
with the indicated concentrations of gp120. At the end of incubation, the concentrations of histamine
(A) and LTC4 (B) were measured in the four supernatants. Each point shows the mean of duplicate
determinations. Each symbol represents the results from an individual donor.
We then cultured HHMCs with increasing concentrations of recombinant gp120 (10 to 60 nM)
for 6 h at 37 ◦C. At the end of this incubation the release of VEGF-A and VEGF-C was assayed in the
supernatants of mast cells. Figure 6 shows the results of three preparations of HHMCs, indicating
that gp120 induced the release of angiogenic (VEGF-A) and lymphangiogenic (VEGF-C) factors
from HHMCs.
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Figure 6. Effect of increasing concentrations of HIV gp120 on the release of VEGF-A (open bars) and
VEGF-C (black bars) from four different preparations of HHMCs. HHMCs were incubated (6 h at 37 ◦C)
in the presence of the indicated concentrations of gp120. Each bar shows the mean ± SEM. * p < 0.05;
** p < 0.01.
3. Discussion
This study shows that primary mast cells isolated from human myocardial tissue can be activated
by a human IgG anti-IgE isolated from the serum of a patient with atopic dermatitis. These results
are compatible with the hypothesis that HHMCs bind IgE, which has a role not only in allergic
diseases [53,88] but also in several cardiovascular disorders [89–91]. Bacterial (protein A and protein L)
and viral (gp120) superantigens can activate HHMCs to release a variety of proinflammatory (histamine,
LTC4, PGD2), angiogenic (VEGF-A), and lymphangiogenic (VEGF-C) mediators. The releasing activity
of protein A and gp120 appears to be mediated by interaction with the VH3 region of IgE on HHMCs.
By contrast, protein L of P. magnus activates HHMCs by interaction with the κ light chains of IgE
on cardiac mast cells. Our findings provide evidence, to our knowledge for the first time, that the
immunologic (human IgG anti-IgE) and superantigenic activation of human myocardial mast cells can
induce the release of angiogenic and lymphangiogenic factors.
Mast cells are present in strategically important locations of murine [43,92] and humanheart [48,49,51,77].
Mast cells are present in atherosclerotic lesions [50,93] and promote atherogenesis [89]. These cells
and their mediators are also involved in cardiometabolic diseases [78], myocardial infarction [76]
and remodeling [94], atrial fibrillation [95], thromboembolism [45,51,96], and myocarditis [74,97,98].
Therefore, understanding how cardiac mast cells participate in these inflammatory disorders could
help in the development of targeted therapies for these common diseases.
Serum IgE levels are elevated in patients with myocardial infarction [90,91] and coronary artery
disease compared to controls [89]. Moreover, IgE and FcεRI are overexpressed in human atherosclerotic
lesions. These findings suggest that mast cells and perhaps other immune cells expressing FcεRI
(e.g., dendritic cells, macrophages, basophils, platelets) [89,99,100] could play a role in the pathogenesis
of human atherosclerosis. Previous studies have demonstrated that autoantibodies anti-IgE and
anti-FcεRI can occur in several immunologic disorders [86,101–104]. In this study we found that a
human IgG anti-IgE induced the release of histamine, VEGF-A, and VEGF-C from HHMCs. To our
knowledge this is the first evidence that cross-linking of IgE on human myocardial mast cells can induce
the release of angiogenic factors. Angiogenesis, the process by which new capillaries develop from
the pre-existing vasculature [105], plays a central role in cardiac pathophysiology [87,106]. VEGF-A is
a pivotal mediator in angiogenesis and is synthesized by several immune cells [61,79,81,82,107–110].
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The possibility that human cardiac mast cells can contribute to myocardial angiogenesis, a process of
major relevance in cardiac pathophysiology [106], requires further investigations.
The mammalian heart is rich of lymphatic vessels [111,112] and their number is increased in
human heart following myocardial infarction, in atherosclerosis lesions, and in endocarditis [113,114].
The involvement of VEGF-C in salt-sensitive hypertension [115,116] and in coronary artery
development [117] further add to the implications of lymphangiogenic factors in cardiovascular
diseases [112]. Our results provide the first indication to our knowledge that immunologic and
superantigenic activation of HHMCs leads to the production of VEGF-C, a major selective mediator of
lymphangiogenesis [112].
S. aureus is an important human pathogen implicated in sepsis and endocarditis [118], and sepsis
is a risk factor for cardiac arrhythmias [119]. This study demonstrates that protein A induces the
release of LTC4 from HHMCs through the interaction of the VH3 region of IgE. These results extend on
the previous observation that protein A induces the in vitro release of histamine from HHMCs [40].
Recently, it has been reported that in vivo challenge with protein A resulted in fatal anaphylaxis
involving VH3+ immunoglobulin interaction on mast cells and basophils [120]. Given the relevance of
histamine and cysteinyl leukotrienes in heart pathophysiology [121–123], our results might explain,
at least in part, how S. aureus can cause heart damage in patients with sepsis.
Protein L synthesized by P. magnus induces the de novo synthesis of PGD2 from HHMCs, by
interacting with the κ light chains of IgE on HHMCs. These results extend previous findings indicating
that protein L induces the release of preformed histamine from HHMC [40]. Therefore, protein L is a
complete secretagogue capable of releasing preformed and de novo synthesized mediators implicated
in cardiovascular pathophysiology [121–124].
Our results provide the first indication that HIV gp120 activates HHMCs, thus acting as Ig
SAg. Previous studies from our group have shown that gp120 induces the release of cytokines
(IL-4 and IL-13) from human basophils [26]. Collectively, these findings support the hypothesis
that virus-bound or shed gp120 [125] can function as a viral superantigen activating HMMCs and
basophils to release proinflammatory mediators (histamine, LTC4), cytokines (IL-4 and IL-13), and
angiogenic/lymphangiogenic factors (VEGF-A and VEGF-C), thus contributing to the dysregulation of
immune system in HIV infection. The successful rollout of anti-viral therapy ensured that HIV infection
is managed as a chronic condition. Persistent inflammation and immune dysregulation associated
with HIV leads to accelerated aging and cardiovascular diseases [34,35,126,127]. HIV-positive persons
are, therefore, exhibiting increasing cardiovascular complications [34,35]. Our results, indicating that
gp120 can induce the release of potent proinflammatory (histamine and LTC4) mediators that exert
cardiovascular effects [121–123] from myocardial mast cells, might explain, at least in part, how HIV
can cause heart damage.
In this study we have identified several immunological, bacterial, and viral products that
activate human cardiac mast cells through the interaction with IgE bound to FcεRI. However, mast
cells can be activated by non-IgE- mediated stimuli such as cytokines (e.g., IL-33, SCF) [65,77,128],
TLR ligands [60,129], and neuropeptides [52,130]. Additional studies are necessary to evaluate the
effects of non-IgE-mediated stimuli on the release of proinflammatory mediators, angiogenic and
lymphangiogenic factors from human cardiac mast cells.
Our study has a limitation which has to be pointed out. It was performed using primary
mast cells isolated from myocardial tissue obtained from patients undergoing heart transplantation.
Thus, these mast cells might have different characteristics from cells obtained from healthy donors.
We have previously had the opportunity to address this important issue by comparing the release of
mediators from mast cells isolated from failing hearts and from subjects who died in accidents without
cardiovascular diseases [77]. We found quantitative, but not qualitative differences in the release of
mediators from “normal” cardiac mast cells when compared with those from explanted hearts.
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In conclusion, our results demonstrate that bacterial and viral immunoglobulin superantigens can
activate primary human cardiac mast cells to release vasoactive and proinflammatory mediators and
angiogenic and lymphangiogenic factors.
4. Materials and Methods
4.1. Reagents
HClO4 (Baker Chemical Co., Deventer, The Netherlands), BSA, piperazine-N,N′-bis
(2-ethanesulfonic acid), L-glutamine, antibiotic-antimycotic solution (10,000 IU penicillin, 10 mg/mL
streptomycin, and 25 µg/mL amphotericin B), hyaluronidase, chymopapain, elastase type I, LTC4, and
PGD2 (Sigma-Aldrich, St. Louis, MO, USA), collagenase (Worthington Biochemical Co., Freehold,
NJ, USA), Hanks’ balanced salt solution and fetal calf serum (FCS) (GIBCO, Grand Island, NY, USA),
deoxyribonuclease I and pronase (Calbiochem, La Jolla, CA, USA), RPMI 1640 with 25 mM HEPES
buffer, Eagle’s minimum essential medium (Flow Laboratories, Irvine, UK), Percoll (Pharmacia Fine
Chemicals, Uppsala, Sweden), (3H)-LCT4 and (3H)-PGD2 (New England Nuclear, Boston, MA, USA)
were commercially purchased. CD117 MicroBead kit was purchased from Miltenyi Biotech (Bologna,
Italy). The rabbit anti-LTC4 and anti-PGD2 antibodies were a gift of Dr. Lawrence M. Lichtenstein (The
Johns Hopkins University, Baltimore, MD, USA). Human IgG anti-IgE was purified from the serum of
a patient with atopic dermatitis as described elsewhere [86].
4.2. Buffers
The Pipes (P) buffer used in these experiments was a mixture of 25 mM Pipes, 110 mM NaCl, 5 mM
KCl, pH 7.37, referred to as P. P2CG, contains, in addition to P, 2 mM CaCl2 and 1 g/L dextrose [49]; pH
was titrated to 7.4 with sodium bicarbonate. PGMD contains 0.25 g/L MgCl2·6H2O, 10 mg/L DNase,
and 1 g/L gelatin in addition to P, pH 7.37.
4.3. Human Monoclonal IgM and IgE and Human Polyclonal IgG
Monoclonal IgM were purified from the serum of patients with Waldenström’s macroglobulinemia
as described elsewhere [77]. IgE myeloma proteins were purified from the serum of three patients
described elsewhere [131,132]. Variable regions of these monoclonal IgM were determined using a
panel of primary sequence-dependent VH and VK family specific reagents that identify framework
regions [133]. Human polyclonal IgG were purified from the serum of healthy donors as described
elsewhere [132].
4.4. Isolation of HHMCs
The study was approved by the Ethics Committee of the University of Naples Federico II (Protocol:
Human MC No 7/19, 05/03/2009). The heart tissue was obtained from patients undergoing heart
transplantation at the Deutsches Herzzentrum, Berlin, mostly for cardiomyopathy [77]. The explanted
heart was immediately immersed in cold (4 ◦C) cardioplegic solution and was processed within 5 to
18 h of removal. Fat tissue, large vessels, and pericardium were removed. The tissue was finely minced
into 2–5 mm fragments, suspended in P buffer (10 mL/g of wet tissue), and washed by centrifugation
3 times. After each centrifugation, the heart fragments were filtered through a 150 µm pore Nytex
cloth (Tetko, Elmsford, NY, USA). Fragments were incubated (15 min, 37 ◦C) under constant stirring in
P buffer containing 10 mg collagenase/g of wet tissue. At the end of the incubation the cell suspension
was filtered through a 150 µm pore Nytex cloth and three additional cycles of enzymatic digestion
were performed. After the last procedure, the cells were centrifuged (150× g, 22 ◦C, 8 min) and
filtered through a 60 µm pore Nytex cloth to remove large particles and large cells (mostly myocytes).
Lastly, cells were washed twice in PGMD by centrifugation (150× g, 22 ◦C, 8 min). Cell pellets were
resuspended in P buffer containing 2% BSA and centrifuged (25× g, 22 ◦C, 2 min) to remove sedimented
myocytes (>100 µm long). Supernatants containing endothelial cells, fibroblasts, and mast cells were
Int. J. Mol. Sci. 2019, 20, 1828 10 of 17
then collected and centrifuged (150× g, 22 ◦C, 8 min). HHMC were partially purified by flotation
through a discontinuous Percoll gradient [77]. The purity of these populations ranged from 0.1% to
18%. The enzymatic dispersion tissue yields ≈ 5 × 104 mast cells per gram of heart tissue. HHMCs
were further purified using a CD117 MicroBead kit sorting system (Miltenyi Biotec, Bologna, Italy).
Mast cell purities using these techniques ranged from 26% to 58% and was assessed by toluidine
blue staining.
4.5. Histamine Release Assay
HHMCs (≈ 3 × 104 mast cells per tube) were resuspended in P2CG, and 0.3 mL of the cell
suspension were placed in 12 × 75 mm polyethylene tubes and warmed to 37 ◦C; 0.2 mL of each
prewarmed releasing stimulus was added, and incubation was continued at 37 ◦C for 45 min [39]. The
reaction was stopped by centrifugation (1000× g, 22 ◦C, 2 min), and the supernatants were stored at
−80 ◦C for subsequent assay of histamine, LTC4, and PGD2 content. The cell-free supernatants were
assayed for histamine with an automated fluorometric technique [134]. To calculate histamine release
as a percentage of total cellular histamine, the “spontaneous” release from mast cells was subtracted
from both numerator and denominator. All values are based on means of duplicate determinations
which differed by less than 10%.
4.6. Immunoassay of LTC4 and PGD2
LTC4 and PGD2 were measured in duplicate determinations by radioimmunoassay [39,135]. The
anti-LTC4 and anti-PGD2 antibodies are highly selective, with less than 1% cross-reactivity to other
eicosanoids [39,135].
4.7. VEGF-A and VEGF-C Release
HHMCs (≈ 4× 104 mast cells/per tube) were incubated (37 ◦C, 6 h) in RPMI 1640 containing 5% FCS,
2 mM L-glutamine, and 1% antibiotic-antimycotic solution, and activated with various concentrations
of stimuli. At the end of incubation, cells were centrifuged (1000× g, 4 ◦C, 5 min) and the supernatants
were stored at −80 ◦C for subsequent determination of mediator release. VEGF-A and VEGF-C
were measured in duplicate determinations using commercially available ELISA kits (R&D System,
Minneapolis, MN, USA) as previously described [136]. The ELISA sensitivity is 31.1–2000 pg/mL for
VEGF-A and 62–4000 pg/mL for VEGF-C.
4.8. Statistical Analysis
Values were expressed as means ± SEM (standard error of the mean). The one-way repeated
measures analysis of variance (ANOVA) with Greenhouse–Geisser corrections was used to examine
the variations of continuous variables at different experimental conditions. Results were analyzed
with GraphPad Prism software (version 8.01; GraphPad Software, La Jolla, CA, USA), and p values of
less than 0.05 were considered significant.
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Abbreviations
S. aureus Staphylococcus aureus
P. magnus Peptostreptococcus magnus
LTC4 Cysteinyl leukotriene C4
HHMCs Human heart mast cells
Ig Immunoglobulin
FcεRI High-affinity receptor for IgE
PGD2 Prostaglandin D2
gp120 Glycoprotein 120
VEGF Vascular endothelial growth factor
SAg Superantigen
APCs Antigen-presenting cells
MHC Major histocompatibility complex
TCR T cell receptor
V Variable
H Heavy
L Light
SE Staphylococcus aureus enterotoxins
IL Interleukin
HIV Human immunodeficiency virus
FCS Fetal calf serum
BSA Bovine serum albumin
H-aIgE Human IgG anti-IgE
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